AKTX
Akari TherapeuticsAKTX
AKTX
About: Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Employees: 12
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% less ownership
Funds ownership: 0% [Q4 2024] → 0% (-0%) [Q1 2025]
4% less capital invested
Capital invested by funds: $394K [Q4 2024] → $377K (-$16.5K) [Q1 2025]
21% less funds holding
Funds holding: 14 [Q4 2024] → 11 (-3) [Q1 2025]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for AKTX.
Financial journalist opinion
Based on 3 articles about AKTX published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates
Neutral
GlobeNewsWire
3 weeks ago
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET.
Neutral
GlobeNewsWire
4 weeks ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Neutral
GlobeNewsWire
1 month ago
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors
Neutral
GlobeNewsWire
1 month ago
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products
Neutral
GlobeNewsWire
1 month ago
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala
Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video here BOSTON and LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced the release of a corporate update video featuring newly appointed President and Chief Executive Officer, Abizer Gaslightwala. The video is now available on the Presentations page under the Investors section of the Company's website (www.akaritx.com).
Neutral
GlobeNewsWire
2 months ago
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B
Neutral
GlobeNewsWire
3 months ago
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds.
Neutral
GlobeNewsWire
3 months ago
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Dr. Samir Patel, President and Chief Executive Officer of Akari Therapeutics, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Akari in 2025.
Neutral
GlobeNewsWire
4 months ago
Akari Therapeutics Joins Webull Corporate Connect Service Platform
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform. Akari's portal on the Webull CCS aims to provide an additional line of communication for shareholders and interested investors and enhance transparency with its growing shareholder base.
Charts implemented using Lightweight Charts™